



**Initial Disclosure Notice**

**Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

|  |
|--|
| To NZX Limited; and                              |
| Name of listed issuer:                           |
| Date this disclosure made:                       |
| Date on which issuer listed or appointment made: |

|                        |
|------------------------|
| Green Cross Health Ltd |
| 7-Apr-22               |
| 6-Apr-22               |

**Director or senior manager giving disclosure**

|   |
|---|
| Full name:                                      |
| Name of listed issuer:                          |
| Name of related body corporate (if applicable): |
| Position held in listed issuer:                 |

|                         |
|-------------------------|
| Craig Michael Brockliss |
| Green Cross Health Ltd  |
| N/A                     |
| Director                |

**Summary of relevant interest (excluding specified derivatives)**

|                                    |
|------------------------------------|
| Class of quoted financial product: |
| Number held in class:              |
| Nature of relevant interest:       |
| Current registered holder:         |

|  |  |  |
|--|--|--|
| Ordinary shares (NZX Code: GXH)  |  |  |
|  | 583,747  | 11,091,195   |
| Craig is a beneficial owner of certain shares held on bare trust by Wilton Asset Management Ltd for Oscar Holdings Ltd, his investment company | Craig is a director and joint shareholder of the holding company of Wilton Asset Management Ltd, which holds shares in Green Cross Health Ltd, and Craig is therefore deemed to have a relevant interest in those shares | Craig is a beneficial owner of certain shares held by Oscar Holdings Ltd, his investment company |
| Wilton Asset Management Ltd  | Wilton Asset Management Ltd  | Oscar Holdings Ltd   |

**Summary of specified derivatives relevant interest (if applicable)**

|   |
|---|
| Type of derivative:                     |
| Class of underlying financial products: |

|     |
|-----|
| n/a |
| n/a |

**Details of derivative**

|   |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying products (if any):   |
| A statement as to whether the derivative is cash settled or physically settled:   |
| Maturity date of the derivative (if any):   |
| Expiry date of the derivative (if any):   |
| The price specified in the terms of the derivative(if any):   |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

|     |
|-----|
| n/a |

For that derivative,-

|  |
|--|
| Parties to the derivative:   |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

|     |
|-----|
| n/a |
| n/a |

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

|                                   |
|-----------------------------------|
| Signature of director or officer: |
| Date of signature:                |

|  |
|--|
|  |
|  |

or

|  |
|--|
| Signature of person authorised to sign on behalf of director or officer: |
| Date of signature:   |
| Name and title of authorised person:                                     |

|                      |
|----------------------|
|                      |
| 7/04/2022            |
| Ben Doshi, Group CFO |